AstraZeneca, Biovail enter into agreement for Zoladex

Share this article:
AstraZeneca and Biovail have entered into an agreement in which Biovail's specialty sales force will promote AstraZeneca's Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. Biovail's 85-member specialty sales force currently promotes Zovirax cream and ointment to specialists and selected primary-care physicians in the US. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?